Clinical Trial

A Study of SRSD384 in Overweight or Obese Participants

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD384 alone in overweight or obese participants (Part A) and in combination with tirzepatide in overweight or obese participants with T2DM (Part B).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-04-22; most recent amendment 2026-06-03.
Trial Details
NCT Number NCT07557355
Lead Sponsor Sirius Therapeutics Co., Ltd.
Conditions Overweight , Obesity
Enrollment 78 participants
Start Date 2026-06
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-05